|Bid||145.00 x 0|
|Ask||150.00 x 0|
|Day's Range||146.00 - 153.20|
|52 Week Range||1.35 - 168.93|
|Beta (5Y Monthly)||0.69|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 19, 2021 - Jul 23, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||625.00|
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Every investor in ReNeuron Group plc ( LON:RENE ) should be aware of the most powerful shareholder groups. Institutions...
LONDON, UK / ACCESSWIRE / January 15, 2021 / After an eventful 2020, ReNeuron released updated 12-month Phase ll data in January on its lead human retinal progenitor cell (hRPC) project. This continues to show a consistent and robust, sustained average gain in visual acuity in retinitis pigmentosa (RP).